GO
Loading...

Sanofi SA

More

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • PARIS, April 8- Things are changing in France's business world. But if you think that signals the end of the Gallic sneer at "Anglo-Saxon" ways- the free-market bent of the Americans and British- last week's promotion to economy minister for the interventionist Arnaud Montebourg is a reminder that laissez-faire government remains, in France, a linguistic irony.

  • April 2- Bill Gates, the World Bank and other donors are stepping up efforts to fight neglected tropical diseases in Africa and other low-income regions with a $240 million injection of new funding. The new collaboration includes $50 million from the Bill& Melinda Gates Foundation and $50 million from the Children's Investment Fund Foundation.

  • *Up to 100 mln pounds for new drug manufacturing in Africa. *GSK looks at Rwanda, Ghana and Ethiopia for new factories. France's Sanofi has also highlighted Africa as a promising market.

  • *Up to 100 mln pounds for new drug manufacturing in Africa. *GSK looks at Rwanda, Ghana and Ethiopia for new factories. France's Sanofi has also highlighted Africa as a promising growth market.

  • *Sanofi hopes to deliver first doses in late 2015. *Sanofi has spent over 1.3 bln euros on project.

  • European shares dip early as China data weighs Monday, 24 Mar 2014 | 5:22 AM ET

    *China's lower-than-expected PMI weighs on sentiment. PARIS, March 24- European stocks slipped in early trade on Monday, trimming last week's lofty gains, as data showing China's manufacturing activity contracted in the first quarter of 2014 revived worries over the outlook for global growth.

  • COPENHAGEN, March 20- Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • Wider market sentiment was still undermined by the crisis in Ukraine, where confrontation between Kiev and Moscow showed no sign of easing. The DAX had fallen 2.9 percent in the previous two sessions, dragged down by worries about Ukraine and by disappointing Chinese trade data.

  • Wider market sentiment was still undermined by the crisis in Ukraine, where confrontation between Kiev and Moscow showed no sign of easing. The DAX had fallen 2.9 percent in the previous two sessions, dragged down by worries about Ukraine and by disappointing Chinese trade data.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • ZURICH, March 7- Novartis drug Jakavi achieved its main goal in a late-stage trial for patients suffering from a rare blood cancer, putting it on track to become a potential blockbuster treatment with sales of $1 billion- plus.

  • Feb 25- Anika Therapeutics Inc said the U.S. Food and Drug Administration approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee, more than four years after it first filed for approval.

  • Feb 25- Vivus Inc's silence on its strategy to boost sales of obesity drug Qsymia has increased doubts about whether the pill will reach its full commercial potential. Analysts said on Tuesday that Vivus, with its limited sales force, needed a partner to ensure the drug's success.

  • NEW YORK/ LONDON, Feb 19- A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck& Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter.

  • Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.

Most Popular Video

Thursday, 17 Apr 2014 | 1:03 PM ET

Dissecting the current market action amid geopolitical concerns, with Kenny Polcari, O'Neil Securities, and CNBC's Dominic Chu.

Thursday, 17 Apr 2014 | 12:06 PM ET

Discussing the case for stocks, with Ed Yardeni, president and chief investment strategist of Yardeni Research. He thinks the market had an "internal correction."

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.